Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.56 USD | -0.71% | -8.40% | +13.70% |
17/05 | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
13/05 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.70% | 178M | |
+8.92% | 114B | |
+10.48% | 104B | |
-1.83% | 22.57B | |
-6.45% | 22.5B | |
-10.39% | 17.95B | |
-42.36% | 16.48B | |
-14.45% | 15.82B | |
+3.76% | 13.55B | |
+28.94% | 10.99B |
- Stock Market
- Equities
- CAPR Stock
- News Capricor Therapeutics, Inc.
- Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M